ArticleInternational urology and nephrology2026
Metformin use linked to decreased risk of pelvic organ prolapse: insights from NHANES data.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposePreclinical evidence suggests that metformin may mitigate pelvic organ prolapse (POP) by altering the gene expression of human vaginal fibroblasts in a beneficial direction, but clinical validation is lacking. This study aimed to explore the association between metformin use and POP risk.
methodsA cross-sectional analysis was conducted using the National Health and Nutrition Examination Survey (NHANES) data from 2005 to 2012. POP was defined by self-reported vaginal bulging. Multivariable logistic regression models were used to assess associations between metformin use and POP in high-risk subgroups (hypertension or smoking), with adjustments for demographic, comorbidity, and obstetric/gynecologic factors. Associations between inflammatory and oxidative stress biomarkers and POP were also analyzed.
resultsThree hundred and thirty of 9344 included women reported POP. Among 668 metformin users (630 with diabetes, 36 with prediabetes), 37 had POP. (Pre)diabetes was a risk factor for POP (OR = 1.52, P = 0.007). POP prevalence was lower in metformin-treated (pre)diabetes subgroups with hypertension (OR = 0.32, P = 0.045) or smoking (OR = 0.09, P = 0.022), independent of glycemic control, while thiazolidinediones, sulfonylureas, and insulin did not show the effect. C-reactive protein was higher in POP individuals (0.56 ± 0.98 mg/dL vs. 0.44 ± 0.73 mg/dL) and associated with POP (OR = 1.30, P = 0.020), especially in smokers (OR = 1.50, P = 0.002), but not in metformin users. Other biomarkers (systemic immune-inflammation index, ferritin, alkaline phosphatase, bilirubin, albumin, iron, γ-glutamyl transferase, and uric acid) showed no significant associations.
conclusionThis is the first clinical study that suggests metformin may reduce POP risk in specific high-inflammatory subgroups, potentially via anti-inflammatory pathways. The findings warrant further prospective studies and mechanistic validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.